Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials

The molecular approach for the analysis of leukemia associated chromosomal translocations has led to the identification of prognostic relevant subgroups. In pediatric acute lymphoblastic leukemia (ALL), the most common translocations, t(9; 22) and t(4; 11), have been associated with a poorer clinical outcome. Recently the TEL gene at chromosome 12p13 and the AML1 gene at chromosome 21q22 were found to be involved in the translocation t(12; 21)(p13; q22). By conventional cytogenetics, however, this chromosomal abnormality is barely detectable and occurs in less than 0.05% of childhood ALL. To investigate the frequency of the molecular equivalent of the t(12; 21), the TEL/AML1 gene fusion, we have undertaken a prospective screening in the running German Berlin-Frankfurt-Munster (BFM) and Italian Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) multicenter ALL therapy trials. We have analyzed 334 unselected cases of pediatric ALL patients consecutively referred over a period of 5 and 9 months, respectively. The overall incidence of the t(12; 21) in pediatric ALL is 18.9%. The 63 cases positive for the TEL/AML1 chimeric products ranged in age between 1 and 12 years, and all but one showed CD10 and pre-B immunophenotype. Interestingly, one case displayed a pre-pre–B immunophenotype. Among the B-lineage subgroup, the t(12; 21) occurs in 22.0% of the cases. Fifteen of 61 (24.6%) cases coexpressed at least two myeloid antigens (CD13, CD33, or CDw65) in more than 20% of the gated blast cells. DNA index was available for 59 of the 63 TEL/AML1 positive cases; a hyperdiploid DNA content (≥1.16) was detected in only four patients, being nonhyperdiploid in the remaining 55. Based on this prospective analysis, we retrospectively evaluated the impact of TEL/AML1 in prognosis by identifying the subset of B-lineage ALL children enrolled in the closed German ALL-BFM-90 and Italian ALL-AIEOP-91 protocols who had sufficient material for analysis. A total of 342 children were investigated for the presence of TEL/AML1 fusion gene and 99 cases (28.9%) were positive. The patients expressing the TEL/AML1 fusion mRNA appeared to have a better event-free survival (EFS) than the patients who lacked this chimeric product. Whereas three of the TEL/AML1 positive cases (3.0%) have relapsed to date, 27 patients without TEL/AML1 rearrangement (11.1%) suffered from relapse. To date, the only subset of B-lineage ALL with a favorable prognosis has been the hyperdiploid group (DNA index ≥1.16 <1.6). Our findings reinforce the need to include the molecular screening of the t(12; 21) translocation within ongoing prospective ALL trials to prove definitively its prognostic impact.

[1]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[2]  W. Hiddemann,et al.  Convention on nomenclature for DNA cytometry , 1984 .

[3]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[4]  I Royston,et al.  Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. , 1987, The New England journal of medicine.

[5]  K. Weinberg,et al.  Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. , 1991, The New England journal of medicine.

[6]  L. Frankel,et al.  Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Kamps,et al.  Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. , 1992, Medical and pediatric oncology.

[8]  S. Raimondi.  Current Status of Cytogenetic Research in Childhood Acute Lymphoblastic Leukemia , 1993 .

[9]  Pui Ch,et al.  Prognostic factors in childhood acute lymphoblastic leukemia. , 1993 .

[10]  T. Barbui,et al.  Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. , 1993, Blood.

[11]  F. Behm,et al.  Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.

[12]  R. Berger,et al.  t( 12;21): A new recurrent translocation in acute lymphoblastic leukemia , 1994, Genes, chromosomes & cancer.

[13]  C. Pui,et al.  Biology and treatment of acute lymphoblastic leukemia , 1994 .

[14]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[15]  P. Marynen,et al.  TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). , 1995, Blood.

[16]  J. Rowley,et al.  Identification of cytogenetically undetected 12p13 translocations and associated deletions with fluorescence in situ hybridization , 1995, Genes, chromosomes & cancer.

[17]  E. Macintyre,et al.  High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. , 1995, Blood.

[18]  P. Riegman,et al.  Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. , 1995, Oncogene.

[19]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[20]  C. Pui.  Medical progress : childhood leukemias , 1995 .

[21]  J. Rowley,et al.  AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. , 1995, Blood.

[22]  D. Le Paslier,et al.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. , 1995, Blood.

[23]  M. Taniwaki,et al.  Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. , 1996, Leukemia.

[24]  J. Rowley,et al.  Correlation between the ETV6/CBFA2 (TEL/AMLI) fusion gene and karyotypic abnormalities in children with B‐cell precursor acute lymphoblastic leukemia , 1996, Genes, chromosomes & cancer.

[25]  A. Borkhardt,et al.  Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. , 1996, Leukemia.

[26]  F. Sigaux,et al.  TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia , 1996 .

[27]  H P Koeffler,et al.  TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. , 1996, Blood.